双能CT用于乳腺癌局部区域分期:初步结果
回顾性纳入2016年1月至2017年7月31例经穿刺活检确诊的乳腺癌患者,术前行增强双能CT,评估40与70 keV单能图像;以术后病理为参考标准。双能CT对34侧乳腺检出67个病灶,病理检出64个;病灶最大径双能CT 33.2±20.5 mm vs 病理31.8±20.5 mm;碘浓度阈值1.70 mg/mL鉴别浸润性癌的敏感度94.9%、特异度93.0%、AUC 0.968。作者认为双能CT用于乳腺癌局部区域分期可行且似乎可靠。
要点
- 双能CT碘浓度阈值1.70 mg/mL鉴别浸润性癌(浸润性小叶癌与浸润性导管癌)与其他病变,敏感度94.9%、特异度93.0%、AUC 0.968。
- 病灶碘浓度与正常乳腺实质碘浓度比值6.13为鉴别浸润性导管癌与其他病变的最佳阈值,敏感度87.0%、特异度81.1%、AUC 0.914。
- 双能CT测量病灶最大径33.2±20.5 mm,病理31.8±20.5 mm;癌灶分布分类正确31/34侧(91%)。
关键影像表现/征象
- 双能CT检出67个病灶,病理检出64个,共34侧乳腺(含3例双侧乳腺癌)。
- 双能CT测得病灶最大径33.2±20.5 mm,病理为31.8±20.5 mm。
- 双能CT对癌灶分布的归类正确31/34侧(91%)。
诊断标准与关键数值
- 病灶碘浓度鉴别浸润性癌(浸润性小叶癌与浸润性导管癌)与其他病变的最佳阈值为1.70 mg/mL,敏感度94.9%、特异度93.0%、AUC 0.968。
- 病灶碘浓度与正常乳腺实质碘浓度比值鉴别浸润性导管癌与其他病变的最佳阈值为6.13,敏感度87.0%、特异度81.1%、AUC 0.914。
- 记录肿瘤与正常乳腺组织的衰减值、碘浓度及二者比值;癌按导管原位癌、浸润性导管癌、浸润性小叶癌分类。
临床应用与阅片要点
- 阅片时可测量病灶碘浓度及其与正常乳腺实质碘浓度的比值,作为鉴别浸润性癌与其他病变的定量参考。
- 报告最大肿瘤直径时注意双能CT测值33.2±20.5 mm与病理31.8±20.5 mm接近,但癌灶分布归类34侧中仅31侧(91%)正确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The objective of this study was to demonstrate the feasibility of dual-energy CT (DECT) for locoregional staging of breast cancer and differentiation of tumor histotypes. MATERIALS AND METHODS. From January 2016 to July 2017, a total of 31 patients (mean [± SD] age, 55.8 ± 14.8 years) with breast cancer diagnosed by needle biopsy who underwent preoperative contrast-enhanced DECT for staging purposes were selected from a retrospective review of institutional databases. Monochromatic images obtained at 40 and 70 keV were evaluated by two readers who determining the number of hypervascularized tumors present and the largest tumor diameter for each breast. The attenuation values and iodine concentration of tumors and normal breast tissue and the ratios of these findings in each tissue type were recorded. Cancers were classified as ductal carcinoma in situ, invasive ductal carcinoma, and invasive lobular carcinoma. The reference standard was the final pathologic finding after surgery. RESULTS. A total of 64 tumor lesions were found at histopathologic analysis versus 67 on DECT for 34 breasts (three bilateral cancers were included). Nonparametric statistics were used. The largest lesion diameter observed DECT was 33.2 ± 20.5 mm versus 31.8 ± 20.5 mm on pathologic analysis, and cancer distribution was correctly classified for 31 of 34 (91%) cases. ROC curves derived from lesion iodine concentration showed that the optimal thresholds for distinguishing infiltrating carcinomas (invasive lobular and ductal carcinomas) and from other lesions were 1.70 mg/mL (sensitivity, 94.9%; specificity, 93.0%; AUC value, 0.968). ROC curves derived from the ratio of the iodine concentration in lesions to that in normal breast parenchyma showed that 6.13 was the optimal threshold to distinguish invasive ductal carcinoma from other lesions (sensitivity, 87.0%; specificity, 81.1%; AUC value, 0.914). CONCLUSION. DECT is feasible and seems to be a reliable tool for locoregional staging of breast cancer.
引用
- Volterrani L, Gentili F, Fausto A, et al. Dual-Energy CT for Locoregional Staging of Breast Cancer: Preliminary Results. AJR Am J Roentgenol. 2020. PMID: 31939699. doi:10.2214/AJR.18.20953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。